Sertraline API Manufacturers & Suppliers

Sertraline (CAS 79617-96-2) is a selective serotonin reuptake inhibitor used globally for major depressive disorder, post‑traumatic stress disorder, obsessive‑compulsive disorder, panic disorder, premenstrual dysphoric disorder, and social anxiety disorder. Additional off‑label applications include post‑stroke depression prevention, generalized anxiety disorder, fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.

Pharmacologically, sertraline is a tametraline derivative that increases serotonergic neurotransmission through potent inhibition of presynaptic serotonin reuptake. This leads to elevated synaptic 5‑HT concentrations and downstream neuroadaptive changes considered central to antidepressant and anti‑obsessional efficacy. It shows minimal binding to GABAergic, dopaminergic, and most serotonergic receptor subtypes, with limited inhibition of norepinephrine and dopamine uptake. Sertraline has measurable affinity for sigma‑1 and sigma‑2 sites, with stronger interaction at sigma‑1. Animal studies demonstrate chronic‑dose down‑regulation of norepinephrine receptors, although the clinical significance remains uncertain.

The pharmacodynamic profile is characterized by lower anticholinergic, antihistaminic, and cardiovascular activity compared with tricyclic antidepressants. Clinical benefit typically emerges after 4 to 6 weeks of therapy, consistent with delayed central adaptation to increased serotonergic tone.

Absorption is moderate and subject to first‑pass metabolism. Sertraline is extensively metabolized by multiple cytochrome P450 pathways, functioning as both a substrate and inhibitor of CYP2C19, CYP2C9, CYP2D6, CYP2B6, and CYP3A isoforms to varying degrees. It also interacts with P‑glycoprotein transport systems. These characteristics influence drug–drug interaction potential. The compound is associated with a known risk of serotonin syndrome when combined with other serotonergic agents and may reduce seizure threshold. Additional safety considerations include hyponatremia, gastrointestinal effects, and photosensitivity.

Sertraline is marketed worldwide under numerous brand and generic formulations for oral administration.

For API procurement, suppliers should demonstrate control of stereochemistry, absence of genotoxic impurities, and consistent polymorphic form, supported by validated analytical methods and compliance with pharmacopeial and GMP standards.